MedTrace Logo

Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB

NCT02496013 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2017-04-07

No results posted yet for this study

Summary

This is an open-label whole-body PET/CT study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 68Ga-NEB in healthy volunteers and patients with suspected infection. Changes of routine blood and urine tests and any adverse events will be collected from the volunteers. Adverse events will also be observed in the patients.

Conditions

  • Arteriovenous Malformation
  • Hemangioma
  • Neoplasms Lymph Nodes
  • Lymphedema

Interventions

DRUG

68Ga-NEB

68Ga-NEB were injected into the patients before the PET/CT scans

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Fang Li, Dr. · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02496013 on ClinicalTrials.gov